

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION  
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR  
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-38853

---

**NGM BIOPHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**333 Oyster Point Boulevard  
South San Francisco, California 94080  
(650) 243-5555**

---

(Address, including zip code, and telephone number,  
including area code, of registrant's principal executive offices)

---

**Common stock, par value \$0.001**

(Title of each class of securities covered by this Form)

---

**None**

(Titles of all other classes of securities for which  
a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input type="checkbox"/>
Rule 15d-22(b)	<input type="checkbox"/>

Approximate number of holders of record as of the certification or notice date: One

---

Pursuant to the requirements of the Securities Exchange Act of 1934, NGM Biopharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

**NGM Biopharmaceuticals, Inc.**

Date: April 15, 2024

By: /s/ David J. Woodhouse  
Name: David J. Woodhouse  
Title: Chief Executive Officer

---